These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11489676)

  • 41. [Not Available].
    Grabli D
    Presse Med; 2017 Mar; 46(2 Pt 1):187-194. PubMed ID: 28233705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of parkinsonism after long-standing cervical dystonia - A cohort.
    Balint B; Mulroy E; Gövert F; Latorre A; Di Lazarro G; Erro R; Batla A; Holton JL; Miki Y; Warner TT; Bhatia KP
    J Neurol Sci; 2021 Aug; 427():117477. PubMed ID: 34015516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
    Niemann N; Jankovic J
    Parkinsonism Relat Disord; 2019 Oct; 67():74-89. PubMed ID: 31272925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetics of dystonia.
    Fuchs T; Ozelius LJ
    Semin Neurol; 2011 Nov; 31(5):441-8. PubMed ID: 22266882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease.
    Kodama M; Kasahara T; Hyodo M; Aono K; Sugaya M; Koyama Y; Hanayama K; Masakado Y
    Am J Phys Med Rehabil; 2011 Feb; 90(2):150-5. PubMed ID: 20975525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
    Linazasoro G
    Neurologia; 2001 Jan; 16(1):17-29. PubMed ID: 11234658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-parkinsonism kindred.
    McKeon A; Ozelius LJ; Hardiman O; Greenway MJ; Pittock SJ
    Mov Disord; 2007 Jul; 22(9):1325-7. PubMed ID: 17516473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation.
    Carecchio M; Picillo M; Valletta L; Elia AE; Haack TB; Cozzolino A; Vitale A; Garavaglia B; Iuso A; Bagella CF; Pappatà S; Barone P; Prokisch H; Romito L; Tiranti V
    Neurogenetics; 2017 Jul; 18(3):175-178. PubMed ID: 28664294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lingual protrusion dystonia: Manifestation during "on" periods in Parkinson's disease.
    Maiola R; Ramirez Gómez CC; Micheli F
    J Neurol Sci; 2016 Nov; 370():256-257. PubMed ID: 27772770
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute challenge with apomorphine and levodopa in Parkinsonism.
    Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
    Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism.
    Hoenicka J; Vidal L; Godoy M; Ochoa JJ; García de Yébenes J
    Mov Disord; 2001 Mar; 16(2):364-6. PubMed ID: 11295799
    [No Abstract]   [Full Text] [Related]  

  • 52. [A case of Parkinson's disease following dystonia].
    Yasuda C; Takei T; Uozumi T; Toyota T; Yuhi T; Adachi H
    Rinsho Shinkeigaku; 2016 Sep; 56(9):600-4. PubMed ID: 27498816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA.
    Camargos S; Scholz S; Simón-Sánchez J; Paisán-Ruiz C; Lewis P; Hernandez D; Ding J; Gibbs JR; Cookson MR; Bras J; Guerreiro R; Oliveira CR; Lees A; Hardy J; Cardoso F; Singleton AB
    Lancet Neurol; 2008 Mar; 7(3):207-15. PubMed ID: 18243799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Baufreton J; Milekovic T; Li Q; McGuire S; Moraud EM; Porras G; Sun S; Ko WKD; Chazalon M; Morin S; Normand E; Farjot G; Milet A; Pype J; Pioli E; Courtine G; Bessière B; Bezard E
    Mov Disord; 2018 Oct; 33(10):1632-1642. PubMed ID: 29756234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to levodopa treatment in dopa-responsive dystonia.
    Nutt JG; Nygaard TG
    Arch Neurol; 2001 Jun; 58(6):905-10. PubMed ID: 11405805
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
    Onofrj M; Paci C; Thomas A
    J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):605-6. PubMed ID: 9771801
    [No Abstract]   [Full Text] [Related]  

  • 58. [Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson's disease patients].
    Sugiyama K; Yokoyama T; Namba H
    Nihon Rinsho; 2000 Oct; 58(10):2115-9. PubMed ID: 11068457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. X-linked recessive dystonia parkinsonism (XDP; Lubag; DYT3).
    Singleton A; Hague S; Hernandez D
    Adv Neurol; 2004; 94():139-42. PubMed ID: 14509666
    [No Abstract]   [Full Text] [Related]  

  • 60. Severe off-period facial dystonia in Parkinson's disease.
    Miranda M; Chaná P
    Mov Disord; 2000 Jan; 15(1):163-4. PubMed ID: 10634259
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.